Skip to navigationSkip to content
Close

More than 110 people are scheduled to testify at today’s FDA hearing on CBD

Read more on Quartz

Contributions

  • The marathon schedule of stakeholders demonstrates this molecule’s potentially massive impact on US health, culture, and corporate bottom lines. But I doubt we'll see anything conclusive from today—rather it's one more step on the long road to regulation.

    sidenote: I'm pretty sure when I tuned into

    The marathon schedule of stakeholders demonstrates this molecule’s potentially massive impact on US health, culture, and corporate bottom lines. But I doubt we'll see anything conclusive from today—rather it's one more step on the long road to regulation.

    sidenote: I'm pretty sure when I tuned into the livestream for a few minutes I heard a speaker utter the phrase "skunky terpenes," which FDA regulators might not be familiar with.